Sultamicillin is an oral form of the antibiotic combination (codrug or mutual prodrug) ampicillin or sulbactam. It contains esterified ampicillin and sulbactam. The pharmacokinetic properties of sultamicillin are improved compared to a combination of ampicillin and sulbactam. Sultamicillin increases the absorption and decreases the chances of diarrhea and dysentery. The inclusion of sulbactam extends ampicillin's spectrum of action to beta-lactamase producing strains of bacteria. Oral sulbactam with parenteral form provides a regimen of continuous sulbactam therapy throughout the treatment, resulting in better clinical results.

Market Analysis and Insights: Global Sultamicillin Market
In 2020, the global Sultamicillin market size was US$ XX million and it is expected to reach US$ XX million by the end of 2027, with a CAGR of XX% between 2021 and 2027
Global Sultamicillin Scope and Market Size
The global Sultamicillin market is segmented by region (country), company, by Type, and by Application. Players, stakeholders, and other participants in the global Sultamicillin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), byType, and by Application for the period 2016-2027.

Segment by Type
Patent
Generic

Segment by Application
Hospital
Drug Store

By Company
Medifarma
Pfizer
Iq Farma
Meiji Holdings
Kalbe
BB Pharma
United Laboratories
Sanbe Farma
LETI Pharma
Hayao Pharmaceutical
Bristol-Myers Squibb
Da Qing Pharmaceutical
Bernofarm
Pharmetique
Amgen
Menarini
Laboratorios Valmorca
Teva

By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Colombia
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE